Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Asset Writedowns and Impairment (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Asset Writedowns and Impairment for 10 consecutive years, with $27000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment rose 102.05% to $27000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.2 million, a 3.03% increase, with the full-year FY2025 number at -$1.2 million, up 3.03% from a year prior.
  • Asset Writedowns and Impairment was $27000.0 for Q4 2025 at Niagen Bioscience, up from -$12000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $435000.0 in Q2 2023 to a low of -$1.3 million in Q1 2025.
  • A 5-year average of -$69950.0 and a median of $16500.0 in 2021 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: soared 8800.0% in 2023, then tumbled 7015.79% in 2024.
  • Niagen Bioscience's Asset Writedowns and Impairment stood at $198000.0 in 2021, then tumbled by 82.32% to $35000.0 in 2022, then crashed by 45.71% to $19000.0 in 2023, then crashed by 7015.79% to -$1.3 million in 2024, then skyrocketed by 102.05% to $27000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Asset Writedowns and Impairment are $27000.0 (Q4 2025), -$12000.0 (Q3 2025), and $89000.0 (Q2 2025).